Summary
- Profile Type
- Business Offer
- POD Reference
- BOJP20230206002
- Term of Validity
- 6 February 2023 - 5 February 2025
- Company's Country
- Japan
- Type of partnership
- Outsourcing agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Japanese company who has been engaged in CRO (Contracted Research Operation) services is looking for EU companies in the sector of pharmaceuticals and biotech to offer their supporting for regulatory process under an outsourcing agreement.
- Full Description
-
This Japanese company has a 35-year-long experience supporting foreign pharmaceuticals and biotech companies by consulting, studying and coordinating that enables to help obtaining official approvals given by Japanese authorities such as PMDA (Pharmaceuticals and Medical Devices Agency).
They also offer to be an ICCC (In-Country Clinical Caretaker) of potential partners that makes ease of entering into the Japanese market without establishing their own representative office or having a specific CRO. In particular, their consultation service helps their clients to get useful tips in making a strategy that is needed to be filed with PMDA.
Since the company notices that the demand for clinical trials and consultations requested by non-Japanese companies is increasing year by year, they would like to collaborate with European Union pharmaceutical and biotech companies. - Advantages and Innovations
-
It is known that Japanese regulatory approval process is quite intricate, especially for non-Japanese companies, even though the Japanese pharmaceutical market size is considered as the second largest in the world, and its growth rate is attractive.
The Japanese company offers support to prepare necessary data and/or document in line with submission of clinical trial-related materials to PMDA.
They offer more than 10 consultation services to potential partner that would help them to fulfil necessary requirements in a timely manner.
The company conduct over 50 protocols of clinical studies from overseas companies based on their 35 years of service. It would help EU companies entering the Japanese market. - Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
-
Potential partner should be a company or R&D organisation in the sector of pharmaceutical or biotech, and the partner does not have any branch or representative office in Japan.
EU CROs can also be considered as potential partners. - Type and Size of Partner
- Big company
- SME <=10
- SME 50 - 249
- R&D Institution
- SME 11-49
- Type of partnership
- Outsourcing agreement
Dissemination
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals
- Sector Groups Involved
- Health
- Targeted countries
- All countries